Olema Oncology
Kamesh Kuchimanchi, Ph.D., joined Olema in July 2022 as Vice President of Regulatory Affairs and Quality Assurance to oversee both Olema’s developmental regulatory approval processes as well as clinical and developmental quality. He brings more than 20 years of pharmaceutical development experience across oncology, immunology, and inflammation therapeutic areas, and he has extensive regulatory expertise across small and large molecules spanning from early research (pre-IND) to commercial stage. Prior to joining Olema Oncology, Dr. Kuchimanchi served as an Executive Director, Head of Regulatory Strategy, Labeling and Promotion at Sumitomo Pharma Oncology. His earlier career included leadership roles at Amgen, Baxter/Baxalta, and Shire. Dr. Kuchimanchi earned his bachelor’s degree in Pharmacy from Birla Institute of Technology, India, and a doctorate in Pharmaceutical Sciences from University of Missouri-Kansas City.
This person is not in any teams
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.